Attana Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Attana's earnings have been declining at an average annual rate of -9.7%, while the Life Sciences industry saw earnings growing at 28.5% annually. Revenues have been growing at an average rate of 1% per year.
Belangrijke informatie
-9.7%
Groei van de winst
3.6%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 31.8% |
| Inkomstengroei | 1.0% |
| Rendement op eigen vermogen | -118.8% |
| Nettomarge | -241.1% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Attana geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 6 | -14 | 14 | 0 |
| 30 Jun 24 | 7 | -12 | 13 | 0 |
| 31 Mar 24 | 7 | -12 | 14 | 0 |
| 31 Dec 23 | 7 | -14 | 16 | 0 |
| 30 Sep 23 | 6 | -15 | 15 | 0 |
| 30 Jun 23 | 7 | -16 | 16 | 0 |
| 31 Mar 23 | 11 | -16 | 18 | 0 |
| 31 Dec 22 | 13 | -15 | 19 | 0 |
| 30 Sep 22 | 14 | -15 | 21 | 0 |
| 30 Jun 22 | 14 | -14 | 22 | 0 |
| 31 Mar 22 | 11 | -15 | 21 | 0 |
| 31 Dec 21 | 8 | -17 | 21 | 0 |
| 30 Sep 21 | 11 | -14 | 21 | 0 |
| 30 Jun 21 | 10 | -13 | 19 | 0 |
| 31 Mar 21 | 9 | -11 | 16 | 0 |
| 31 Dec 20 | 7 | -11 | 14 | 0 |
| 30 Sep 20 | 5 | -11 | 13 | 0 |
| 30 Jun 20 | 4 | -11 | 12 | 0 |
| 31 Mar 20 | 6 | -9 | 12 | 0 |
| 31 Dec 19 | 8 | -7 | 13 | 0 |
| 30 Sep 19 | 8 | -6 | 12 | 0 |
| 30 Jun 19 | 8 | -4 | 12 | 0 |
| 31 Mar 19 | 6 | -6 | 12 | 0 |
| 31 Dec 18 | 5 | -6 | 12 | 0 |
| 30 Sep 18 | 5 | -6 | 12 | 0 |
| 31 Dec 17 | 4 | -7 | 10 | 0 |
| 31 Dec 16 | 9 | -4 | 11 | 0 |
| 30 Jun 16 | 6 | -3 | 8 | 0 |
| 30 Jun 15 | 5 | -2 | 8 | 0 |
| 30 Jun 14 | 3 | -2 | 6 | 0 |
Kwaliteitswinsten: ATANA is currently unprofitable.
Groeiende winstmarge: ATANA is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ATANA is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Versnelling van de groei: Unable to compare ATANA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ATANA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (36%).
Rendement op eigen vermogen
Hoge ROE: ATANA has a negative Return on Equity (-118.82%), as it is currently unprofitable.